LXEO

Lexeo Therapeutics, Inc. | Cotação de Ações

Última atualização19/09/2025, 17:00:03

PreçoUS$ 5,15

Variação (dia)-US$ 0,31 (-5.68%)▼

Min. 52 SemanasUS$ 1,45

Máx. 52 SemanasUS$ 11,72

Capitalização de mercado--

Endereço: 345 Park Avenue South, New York, NY, 10010

Telefone: 212 547 9879

Funcionários: 61

Lexeo Therapeutics, Inc.LXEO

US$ 5,15

- 0,315,7%

19/09/2025 17:00:03

1D 7D 1M 3M 1A Tudo

Visão geral da empresa

Preço atualUS$ 5,15

Valor de mercado--

AberturaUS$ 5,30

Preço máximoUS$ 5,53

Preço mínimoUS$ 5,15

VolumeUS$ 1,3 mi

Fechamento anteriorUS$ 5,46

Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy. The company also develops LX2022, a gene therapy candidate, which is in preclinical trial to deliver a functional TNNI3 gene to myocardial cells to treat a distinct form of hypertrophic cardiomyopathy. In addition, it is developing LX1001, an AAVrh10-based gene therapy candidate, which has completed phase 1/2 clinical trial for the treatment of APOE4-associated Alzheimer's disease. The company has license agreement with Cornell University to conduct of the Phase 1/2 clinical trial of LX1001, as well as support the development of LX1004 program; research collaboration agreement with Cornell University to conduct preclinical research to develop the licensed technology; and third license agreement which obtained certain rights for FA cardiomyopathy, including rights to current and future clinical data from an ongoing Cornell University investigator-initiated Phase 1A trial of a gene therapy candidate. The company was founded in 2017 and is headquartered in New York, New York.

Ações relacionadas

CARGO Therapeutics, Inc.

CRGX ▼0.01% | US$ 13,65

Mineralys Therapeutics, Inc.

MLYS ▼0.14% | US$ 9,86

Apogee Therapeutics, Inc.

APGE ▼0.09% | US$ 40,13

Neumora Therapeutics, Inc.

NMRA ▲0.01% | US$ 2,01

Kyverna Therapeutics, Inc.

KYTX ▼0.02% | US$ 3,57

Encontre respostas para suas dúvidas sobre investimentos em nossa seção de Perguntas Frequentes (FAQ)

Acesse a seção de Perguntas Frequentes da brapi para esclarecer dúvidas sobre investimentos. Nossa FAQ fornece informações concisas, abordando tópicos relevantes para investidores, contribuindo para uma compreensão mais clara do mercado financeiro.

Fique por dentro das últimas notícias do mundo financeiro em nosso Blog

Mantenha-se atualizado com as últimas notícias financeiras em nosso Blog. Publicamos artigos informativos e análises de especialistas para fornecer insights valiosos sobre o cenário financeiro em constante evolução.

Assine nossa newsletter para receber atualizações gratuitas por e-mail

Mantenha-se informado assinando nossa newsletter. Receba atualizações gratuitas por e-mail, incluindo rendimentos, novidades do mercado e insights valiosos. Estamos comprometidos em fornecer informações relevantes diretamente à sua caixa de entrada.